Notice
UEG Week Virtual 2020 Celltrion Healthcare Industry Symposium
등록일
2020-09-16
Subcutaneous infliximab has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation, including for the treatment of IBD in June 2020. During the United European Gastroenterology Week virtual 2020 held from October 11 to 13, a symposium is hosted by Celltrion Healthcare to review the latest clinical evidence for infliximab SC, explore bio-innovative approaches with biologic development, and discuss clinical practice of infliximab in the era of COVID-19.